|By PR Newswire||
|April 11, 2014 08:01 AM EDT||
NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
MannKind Corp. Analyst Notes
On April 1, 2014, MannKind Corp. (MannKind) announced that the U.S. Food and Drug Administration (FDA) voted 13 to 1 in recommendation of AFREZZA's market approval. The Company stated that if approved, AFREZZA would be the first ultra rapid-acting mealtime insulin therapy available in the US. "We are pleased with the Advisory Committee's approval recommendation in support of AFREZZA, and we appreciate the thoroughness of their review," said Alfred Mann, Chairman and CEO of MannKind Corporation. "We look forward to working with the FDA as they complete their evaluation of AFREZZA." MannKind informed that the FDA will consider its guidance in reviewing the New Drug Application (NDA) that was submitted for AFREZZA, and Prescription Drug User Fee Act (PDUFA) date for the FDA to complete its review of AFREZZA is April 15, 2014. The full analyst notes on MannKind Corp. are available to download free of charge at:
Acceleron Pharma, Inc. Analyst Notes
On March 24, 2014, Acceleron Pharma, Inc. (Acceleron) and Celgene Corp. (Celgene) announced the successful publication of two papers online and in the April issue of the Nature Medicine journal. The Company stated that the papers explain how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice. According to Acceleron, the studies suggest that sotatercept and ACE-536 may promote and regulate the maturation of late-stage red blood cell precursors and this distinct activity supports the rationale for sotatercept and ACE-536 as potential novel therapies to correct anemia, including the EPO-resistant anemia, in diseases such as beta-thalassemia and myelodysplastic syndromes. The Company added that the two papers will be available on the Publications page of its website. The full analyst notes on Acceleron Pharma, Inc. are available to download free of charge at:
Steris Corp. Analyst Notes
On April 1, 2014, STERIS Corp. (STERIS) announced that it has entered into a definitive agreement to acquire Integrated Medical Systems International, Inc. (IMS) for $165 million. The Company stated that IMS is a privately held business, and an endoscope repair, surgical instrument management and sterile processing consulting company. According to STERIS, IMS will be integrated into the Company's Healthcare segment as part of the Company's Specialty Services business upon the closing of the transaction. "A key element of our growth strategy has been to expand our Specialty Services business through a combination of organic growth and acquisition," said Walt Rosebrough, President and CEO of STERIS Corporation. "We are excited about this opportunity to build upon what we do best - help our hospital Customers improve processes, increase quality, and save money." The Company informed that the transaction is anticipated to close in Q1 FY 2015. The full analyst notes on STERIS Corp. are available to download free of charge at:
Retrophin, Inc. Analyst Notes
On March 27, 2014, Retrophin, Inc. (Retrophin) announced the completion of acquisition of Manchester Pharmaceuticals LLC for $62.5 million. The Company said that the acquisition adds two FDA approved products to Retrophin including Chenodal, for patients suffering from gallstones whom surgery poses an unacceptable health risk due to disease or advanced age and Vecamyl for the management of moderately severe to severe essential hypertension and uncomplicated cases of malignant hypertension. "The acquisition of Manchester Pharmaceuticals is a transformative event for Retrophin, as we are now a commercial company with two FDA-approved products on the market," said Martin Shkreli, Founder and CEO of Retrophin. "We also look forward to raising awareness of CTX, a rare, underdiagnosed and severe disease that is treated with chenodeoxycholic acid. Early diagnosis of CTX is essential, as many patients have permanent neurological damage that could be avoided if the disease is detected early. As such, we are building a team of medical science liaisons who will help educate physicians about CTX." The full analyst notes on Retrophin, Inc. are available to download free of charge at:
NxStage Medical, Inc. Analyst Notes
On March 31, 2014, NxStage Medical Inc. (NxStage) announced that it has been the recipient of 2014 Workplace Hero Award by the Northeast Chapter of the American Red Cross. The Company stated that this award recognizes its continuous efforts to provide support for the disadvantaged and dedication to preparing employees to volunteer in the event of local and national disasters. "We are honored to receive the American Red Cross Northeast Chapter's Workplace Hero Award," stated Jeffrey Burbank, CEO of NxStage. "Giving back is in our DNA - it's crucial not only to those with kidney disease, but also to those in need in our own backyard." The full analyst notes on NxStage Medical, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Aug. 3, 2015 06:45 PM EDT Reads: 520
Aug. 3, 2015 05:45 PM EDT
Aug. 3, 2015 04:30 PM EDT Reads: 206
Aug. 3, 2015 04:00 PM EDT Reads: 272
Aug. 3, 2015 03:45 PM EDT
Aug. 3, 2015 03:30 PM EDT Reads: 236
Aug. 3, 2015 03:30 PM EDT
Aug. 3, 2015 03:15 PM EDT
Aug. 3, 2015 03:00 PM EDT Reads: 559
Aug. 3, 2015 12:30 PM EDT Reads: 206
Aug. 3, 2015 09:45 AM EDT Reads: 365
Aug. 3, 2015 07:30 AM EDT Reads: 188
Aug. 2, 2015 10:00 PM EDT Reads: 684
Aug. 2, 2015 06:00 PM EDT Reads: 1,138
Aug. 2, 2015 04:00 PM EDT Reads: 433